MedPath

iDose TR

These highlights do not include all the information needed to use iDose TR safely and effectively. See full prescribing information for iDose TR. iDose TR (travoprost intracameral implant), for intracameral administration Initial U.S. Approval: 2001

Approved
Approval ID

92f6d3e2-8328-47df-972c-23008f4a1c1c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 20, 2023

Manufacturers
FDA

Glaukos Corporation

DUNS: 012835406

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Travoprost Intracameral

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code25357-100
Application NumberNDA218010
Product Classification
M
Marketing Category
C73594
G
Generic Name
Travoprost Intracameral
Product Specifications
Route of AdministrationINTRACAMERAL
Effective DateDecember 20, 2023
FDA Product Classification

INGREDIENTS (1)

TRAVOPROSTActive
Quantity: 75 ug in 1 1
Code: WJ68R08KX9
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

iDose TR - FDA Drug Approval Details